Form 8-K - Current report:
SEC Accession No. 0001824293-24-000153
Filing Date
2024-11-14
Accepted
2024-11-14 16:24:37
Documents
17
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K val-20241114.htm   iXBRL 8-K 25154
2 EX-99.1 ex991_pressreleaseq32024ea.htm EX-99.1 21859
6 GRAPHIC image_0a.jpg GRAPHIC 38371
7 GRAPHIC val-20241114_g1.jpg GRAPHIC 16879
8 GRAPHIC val-20241114_g2.jpg GRAPHIC 1656
  Complete submission text file 0001824293-24-000153.txt   265402

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT val-20241114.xsd EX-101.SCH 1794
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT val-20241114_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT val-20241114_pre.xml EX-101.PRE 13590
19 EXTRACTED XBRL INSTANCE DOCUMENT val-20241114_htm.xml XML 2906
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037 (619) 400-1171
GRI Bio, Inc. (Filer) CIK: 0001824293 (see all company filings)

EIN.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40034 | Film No.: 241462879
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)